The "New Menopause" Playbook: What Mary Claire Haver Gets Right (And Where Clinicians Add Nuance)

Mary Claire Haver, MD, did something the U.S. medical system spent two decades failing to do: she put perimenopause into the everyday conversation. A board-certified OB/GYN with a #1 New York Times bestseller (“The New Menopause”) and an audience that runs into the millions across TikTok, Instagram, and YouTube, she normalized the symptom list, named the toolkit, and pushed menopausal hormone therapy back onto the table for women who had been told for twenty years to white-knuckle through.

That cultural shift is worth saying plainly: it made our patients’ lives easier. Women now arrive at the consult already knowing the names of their symptoms and the broad shape of the options. That’s a real gift to clinicians, and to the women themselves.

This article is a respectful “yes, and.” Haver’s framework agrees with the medical literature on most of the big pillars. There are a few places where individual care has to refine the message — usually because population-level advice can’t capture the variability of one patient sitting across from one nurse practitioner. Those are the places worth being honest about.

Haver’s “Pause Life” toolkit, and the chapters of “The New Menopause,” organize around a small number of pillars: menopausal hormone therapy (MHT) when appropriate, protein-forward nutrition, resistance training, sleep, stress and mental health, and symptom-by-symptom literacy. The simple test for whether a framework is good is whether the pillars hold up against primary evidence. These largely do.

MHT, within the window, for symptomatic women. This is the headline pillar, and as of February 2026 it is no longer a contested position — it is the FDA label. The Department of Health and Human Services and the FDA announced in November 2025 that the broad “black box” warnings on menopause hormone therapy were being withdrawn; the change was finalized in early 2026. The new label specifically notes that women who initiate MHT within 10 years of menopause and under age 60 may see net benefit beyond symptom relief. The broader public-facing message — that HRT is reasonable for most healthy women within the window — which two years ago put many advocates sideways with portions of the medical establishment, is now aligned with the regulatory language, not contradicting it.

Resistance training for bone and body composition. A 2025 systematic review and meta-analysis of 17 randomized controlled trials in postmenopausal women (Journal of Orthopaedic Surgery and Research) concluded that resistance training significantly improves bone mineral density at the lumbar spine, femoral neck, and total hip, with the strongest effects at ≥3 sessions per week at higher intensities. A separate 2025 network meta-analysis confirmed combined aerobic and resistance training as the most consistent non-pharmacologic intervention for bone health in this population. The “lift heavy things” message Haver and many of her peers have made viral is supported by the data.

Protein intake above the RDA. The current adult RDA of 0.8 g/kg/day is, by the literature’s own framing, a minimum to prevent deficiency, not an optimal intake for preserving muscle and bone in midlife. Multiple recent reviews and position statements suggest 1.0–1.2 g/kg/day, and up to 1.6 g/kg/day in active women, as the more defensible target for perimenopausal and postmenopausal women — with the important caveat that protein only does the work when paired with resistance training. Haver’s protein message is in line with this body of evidence.

Sleep and mental health as first-line, not afterthought. Sleep disruption and mood changes are core perimenopausal symptoms, not character flaws. Haver’s insistence that they be addressed directly — sometimes with hormones, sometimes with SSRIs or CBT-I, sometimes with both — mirrors what The Menopause Society’s position statements have said for years. The shift here is mostly that she made the broader public take the message seriously.

This is the part of the conversation that population-level content can’t carry. The framework is right; the application is individual.

Dosing and formulation are not one-size. Haver herself has been clear in interviews and in her own clinic content that transdermal estrogen is generally preferred over oral, and that transdermal testosterone at roughly 10% of the male dose is the route she favors for women — not pellets. That nuance sometimes gets lost in short social clips, where the takeaway compresses to get on hormones without the formulation specifics. A consult-level decision still depends on personal and family history, baseline labs, symptom profile, route of delivery, and progestogen choice for women with a uterus. The literature supports the broad pillar; the prescription supports the individual.

Compounded products are a real category, used selectively. Compounded bioidentical menopausal hormone therapy — particularly subcutaneous pellets — has been the subject of three converging society statements: NAMS/The Menopause Society 2022, ACOG’s November 2023 Clinical Consensus, and a 2025 critical review of compounded hormonal pellets in the peer-reviewed literature. All three caution against routine prescribing of compounded BHRT as a default, citing supraphysiologic levels, inconsistent dosing, and reports of mood, hair, and bleeding changes. The 2026 FDA label change applies to FDA-approved products, not to compounded ones. There is a legitimate role for compounded therapy in specific clinical situations — allergies to inactive ingredients in approved products, doses or combinations not commercially available — but it should be a deliberate choice with informed consent rather than the default option.

Supplements are where the evidence runs thinnest. This isn’t unique to Haver — it’s true of nearly every menopause-content creator and most clinic websites, including ones that sell supplements. The literature on specific botanicals (black cohosh, red clover, evening primrose), on routine high-dose collagen for joint pain, and on omega-3 dosing for hot flashes is mixed at best and frequently underwhelming. The reasonable clinician position is: a few supplements have decent evidence for specific symptoms; most don’t; and the protein/strength/sleep pillars do more for body composition than any pill in the cabinet. We tell patients which is which and don’t oversell what isn’t there.

It’s tempting in a clinical article to focus on the refinements and lose sight of the bigger point. The bigger point is this: a generation of women were told their symptoms were either inevitable or imagined, and that hormones were too dangerous to consider. That was wrong on both counts, and the people who pushed back against it — Haver among them, but also Avrum Bluming and Carol Tavris (“Estrogen Matters”), Lisa Mosconi at Weill Cornell, the Menopause Society leadership, and many practicing clinicians who simply kept prescribing — did real public-health work.

The result, by 2026, is a measurable shift. Searches for “perimenopause” climbed steadily through 2023–2025. Patients who used to apologize for asking about hormones now ask. Internists and primary-care clinicians who weren’t trained on menopause are being asked to be trained on it, because the demand has reached their inboxes. The FDA label change is downstream of that cultural pressure as much as it is of the evidence re-analyses.

For clinicians who actually do this work day-to-day, that’s good news. It is much easier to have a careful, individualized conversation with a patient who already knows the basic vocabulary than to start from square one on whether hormones are safe to consider at all. We start the conversation closer to the finish line now.

Done well, midlife hormone care follows the same pattern whether the patient arrived from a TikTok rabbit hole or from her primary’s referral. A thorough intake: symptoms, history, family history, current medications, contraindications. Baseline labs, including thyroid and lipids and — where indicated — sex hormones, with the caveat that labs alone don’t make the diagnosis in perimenopause. A treatment plan that may include MHT, may include targeted non-hormonal Rx, may include referral to a pelvic-floor PT or sleep specialist or therapist, and almost always includes the strength-and-protein pillars Haver popularized. Follow-up that catches what a single appointment can’t.

The pillars Haver named are not the property of any one clinician — they’re the evidence. What individual care adds is the dose, the route, the progestogen choice, the timing decision, and the ongoing monitoring that makes the plan actually work for one specific woman.

If you’ve read “The New Menopause,” followed the broader conversation, and are ready to sit with a clinician and turn the framework into your own plan, that’s exactly the kind of conversation we have at Naya Wellness. Carolyn Pampalone, MSN, FNP-BC, has spent nearly two decades in women’s health and hormone care, and our team has the time and the labs and the follow-up infrastructure that a 15-minute primary-care visit can’t offer. You can talk it through at our Chatsworth or Santa Barbara clinics, or by telehealth across California.

Two California locations and statewide telehealth — click a card to view details, or call to schedule a consult.